{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% CI was not estimable due to censoring.","groupId":"OG000","lowerLimit":"9.20","upperLimit":"NA","value":"21.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"TTP was defined as the time from the date of first dose of study drug to the date of first documentation of PD. PD was defined as ≥25% increase from lowest value in serum M component or urine M-component; difference between involved and uninvolved FLC levels (absolute increase \\>10 mg/dL); bone marrow plasma cell percent ≥10%; new bone lesions or soft tissue plasmacytomas development or definite increase in existing bone lesions/soft tissue plasmacytomas size; hypercalcaemia development.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ixazomib 3 mg, capsules, orally, once on Days 1, 8, and 15 for Cycles 1 through 4, during which if the participants tolerated the initial dose, the dose was escalated to ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15 for Cycles 5 through 26, or until documented progressive disease (PD) or intolerable toxicity, whichever occurred first (cycle length=28 days).","id":"OG000","title":"Ixazomib"}],"paramType":"MEDIAN","populationDescription":"Efficacy Population included all participants who received ixazomib treatment for the duration of their study participation. As prespecified in the SAP, the Efficacy Population contained only one arm i.e., Ixazomib (efficacy outcomes data for the participants who received placebo before Protocol Amendment 8 was not collected per SAP), thus data is presented accordingly.","reportingStatus":"POSTED","timeFrame":"Up to 58.4 months","title":"Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"months"}